Nancy K Leidy 1 , Fernando J Martinez 2 , Karen G Malley 1 , David M Mannino 3 , MeiLan K Han 4 , Elizabeth D Bacci 5 , Randall W Brown 6 , Julia F Houfek 7 , Wassim W Labaki 4 , Barry J Make 8 , Catherine A Meldrum 4 , Wilson Quezada 9 , Stephen Rennard 10 , Byron Thomashow 9 , Barbara P Yawn 11
13 June 2018
COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE™) uses five questions and peak expiratory flow (PEF) thresholds (males ≤350 L/min; females ≤250 L/min) to identify patients with a forced expiratory volume in 1 second (FEV 1)/forced vital capacity (FVC) <0.70 and FEV 1 <60% predicted or exacerbation risk requiring further evaluation for COPD. This study tested CAPTURE’s ability to identify symptomatic patients with mild-to-moderate COPD (FEV 1 60%–80% predicted) who may also benefit from diagnosis and treatment.
Data from the CAPTURE development study were used to test its sensitivity (SN) and specificity (SP) differentiating mild-to-moderate COPD (n=73) from no COPD (n=87). SN and SP for differentiating all COPD cases (mild to severe; n=259) from those without COPD (n=87) were also estimated. The modified Medical Research Council (mMRC) dyspnea scale and COPD Assessment Test (CAT™) were used to evaluate symptoms and health status. Clinical Trial Registration: NCT01880177, https://ClinicalTrials.gov/ct2/show/NCT01880177?term=NCT01880177&rank=1.
Mean age (+SD): 61 (+10.5) years; 41% male. COPD: FEV 1/FVC=0.60 (+0.1), FEV 1% predicted=74% (+12.4). SN and SP for differentiating mild-to-moderate and non-COPD patients (n=160): Questionnaire: 83.6%, 67.8%; PEF (≤450 L/min; ≤350 L/min): 83.6%, 66.7%; CAPTURE (Questionnaire+PEF): 71.2%, 83.9%. COPD patients whose CAPTURE results suggested that diagnostic evaluation was warranted (n=52) were more likely to be symptomatic than patients whose results did not (n=21) (mMRC >2: 37% vs 5%, p<0.01; CAT>10: 86% vs 57%, p<0.01). CAPTURE differentiated COPD from no COPD (n=346): SN: 88.0%, SP: 83.9%.